The UK has moved from pledge to statute. The Biodiversity Beyond National Jurisdiction Act 2026 received Royal Assent on 12 February 2026, creating the domestic framework to implement the UN High Seas Treaty and paving the way for UK ratification once secondary rules are laid. The UN agreement itself entered into force on 17 January 2026. (hansard.parliament.uk)

For operators, the scope is clear and commercial. Any UK‑linked expedition using a vessel or craft to collect marine genetic resources on the high seas will fall under the new pre‑ and post‑collection rules. Any UK‑based project that uses those resources-or even just their digital sequence information-must meet new reporting and data‑deposit duties. UK repositories and UK‑controlled public databases that hold samples or sequence data also pick up access and usage‑reporting obligations. Several operative sections will start on dates set by regulations, so compliance teams should prepare now for a staged switch‑on. (bills.parliament.uk)

Expeditions face a long runway. Before a UK craft collects marine genetic resources in areas beyond national jurisdiction, the project lead must submit the Article 12(2) pre‑collection pack to the Secretary of State and then wait at least seven months. That wait can be shortened only where the Secretary of State gives written reasons that a compelling case exists. Plan sampling windows with this clock in mind. (bills.parliament.uk)

After the last sample is taken, the same project lead must file the Article 12(5) post‑collection report as soon as all details are available and no later than 11 months from the final collection day. Missing these dates risks regulatory action once enforcement provisions are commenced. Build these steps into cruise close‑out checklists. (bills.parliament.uk)

Laboratories have a three‑year backstop. Where UK utilisation involves physical material from the high seas, samples must be placed in a publicly accessible repository that follows international practice. Where utilisation involves digital sequence information, those sequences must be recorded in a publicly accessible database consistent with international norms. In both cases, deposits must be made within three years of the project’s start and must be linked to the treaty’s Article 12(3) standardised identifier. Think ENA/GenBank/DDBJ for DSI and recognised culture collections for samples. (bills.parliament.uk)

Outputs trigger fast notifications. If utilisation leads to a publication, a patent application, a product in development or other Article 12(8) outcomes, the project lead has one month to notify the Secretary of State. If a product reaches the market, a one‑month initial notification is followed by annual updates for as long as it remains available. These are short, investor‑relevant clocks-coordinate R&D, IP counsel and regulatory affairs early. (bills.parliament.uk)

Openness is the default. Subject to national security and specific treaty carve‑outs, the Secretary of State may transmit collection and utilisation information to the treaty’s Clearing‑House Mechanism. Repository managers in the UK must ensure samples can be identified as high‑seas in origin-ideally via the Article 12(3) identifier-provide access for utilisation, and report, every two years, how often samples were provided. Database controllers must do the same for digital sequence views and downloads. Reports are due within two months of each relevant two‑year period, or in line with any timetable set by the treaty’s access and benefit‑sharing committee. (bills.parliament.uk)

Access can be conditional, but not closed. The Act allows access to be subject to conditions aligned with Article 14(4)-for example, to reflect conservation aims or practical constraints-while keeping data and samples publicly reachable. For biotech and pharma, that means planning for open data norms with sensible guardrails rather than exclusive control. (bills.parliament.uk)

The money question sits with the treaty’s COP. The Act empowers ministers to implement Conference of the Parties decisions on monetary benefit‑sharing, including requiring disclosures that underpin any payment calculation and the payments themselves. No percentages are set in UK law; finance leaders should stress‑test margins and contracts for a future variable levy tied to high‑seas genetic resource utilisation. (lordslibrary.parliament.uk)

Licensing and impact assessment shift too. The Marine and Coastal Access Act 2009 and the Marine (Scotland) Act 2010 can now be used to bring specific high‑seas activities into marine licensing when needed to deliver high‑seas protected areas or environmental impact assessments under the treaty. The EIA regulations in England and Scotland are amended so that, for BBNJ activities, an EIA is required where there are reasonable grounds to believe an activity may cause substantial pollution or significant and harmful changes to the marine environment. Regulators must also flag EIA where effects may be more than minor or transitory, or are unknown or poorly understood. (bills.parliament.uk)

Enforcement has teeth, especially in emergencies. Following a COP emergency decision, ministers can issue binding directions to UK craft; failure to comply without reasonable excuse is a criminal offence carrying up to two years’ imprisonment or a fine. Expect vessel operators and ROV teams to receive time‑bound instructions if emergency measures are adopted on the high seas. (bills.parliament.uk)

There are carve‑outs. Normal fishing under UK licences, activities done to deliver the Fisheries Act 2020 scientific evidence objective, military activities, and anything done in Antarctica or involving Antarctic genetic resources sit outside these parts of the regime. This keeps fisheries science and defence operations on their current legal tracks while the commercial research rules tighten elsewhere. (bills.parliament.uk)

Devolution matters. Scotland and Northern Ireland gain powers to make their own regulations to implement Part 2 obligations within devolved competence. Businesses operating UK‑wide should expect parallel, not identical, statutory instruments and align compliance plans across borders accordingly. (lordslibrary.parliament.uk)

Timing is the hidden risk. Although the Act is now on the statute book, key sections-covering collection, utilisation, data‑handling and parts of the licensing regime-will commence by regulations. The first two‑year reporting window for repositories and databases will begin on the date the treaty enters into force for the UK after ratification, if that is later than 17 January 2026. Government has signalled that a small set of statutory instruments, including on defining digital sequence information, will follow Royal Assent before the UK deposits its instrument of ratification. (hansard.parliament.uk)

What to do now. Map any project that samples, sequences, screens or commercialises high‑seas material. Name the “relevant person” for each project; build the seven‑month notice and 11‑month reporting points into plans; choose public repositories and databases that meet international practice; and tag everything with Article 12(3) identifiers. Update material transfer agreements and IP workflows around the one‑month notification rule, and budget for potential COP‑driven benefit‑sharing. Treat September 2026 as a realistic earliest sampling window if you file pre‑collection information this month and no ministerial fast‑track is granted. (bills.parliament.uk)

Why this is market‑relevant. For biotech and pharma, transparent DSI pipelines and early‑stage benefit‑sharing modelling become part of cost of goods and partner negotiations. For marine tech and subsea operators, EIA thresholds and possible licensing in areas beyond national jurisdiction add time and certainty costs to deployments. The upside is regulatory clarity: the UK now has a route to participate fully in high‑seas conservation and research, aligning commercial activity with a rules‑based system recognised by major economies. (un.org)